BACKGROUND: Proteinuria predicts progressive renal failure. Next to being a progression marker, non-selective proteinuria itself is thought to be toxic to the tubulointerstitium. In proteinuric states, activation of filtered or locally produced complement is toxic for renal tubular cells and likely contributes to the progression of renal failure. Recent experimental evidence suggests an important role for properdin in promoting intrarenal complement activation. We measured properdin in proteinuric urine and assessed its relation with urinary SC5b-9 levels, the soluble form of the effector phase of complement activation. METHODS: Seventy patients with renal disease of different origin but all with a protein excretion of at least 1 g/day were studied. Urinary properdin and SC5b-9 levels were measured using an ELISA technique. RESULTS: Properdin was detectable in the urine of 37 patients (53%). These subjects had higher urinary SC5b-9 levels {median 0.50 U/ml [interquartile range (IQR) 0.13-1.81] versus 0.049 U/ml (IQR 0.024-0.089), P < 0.001}. When adjusted for proteinuria and renal function, properdin excretion was strongly associated with increased urinary SC5b-9 levels (odds ratio 16.2, 95% confidence interval 3.6-74.4). Properdin excretion was associated with worse renal function. CONCLUSION: Our results suggest that urinary properdin excretion enhances intrarenal complement activation and thus may contribute to the progression of renal damage in proteinuric states.
BACKGROUND:Proteinuria predicts progressive renal failure. Next to being a progression marker, non-selective proteinuria itself is thought to be toxic to the tubulointerstitium. In proteinuric states, activation of filtered or locally produced complement is toxic for renal tubular cells and likely contributes to the progression of renal failure. Recent experimental evidence suggests an important role for properdin in promoting intrarenal complement activation. We measured properdin in proteinuric urine and assessed its relation with urinary SC5b-9 levels, the soluble form of the effector phase of complement activation. METHODS: Seventy patients with renal disease of different origin but all with a protein excretion of at least 1 g/day were studied. Urinary properdin and SC5b-9 levels were measured using an ELISA technique. RESULTS: Properdin was detectable in the urine of 37 patients (53%). These subjects had higher urinary SC5b-9 levels {median 0.50 U/ml [interquartile range (IQR) 0.13-1.81] versus 0.049 U/ml (IQR 0.024-0.089), P < 0.001}. When adjusted for proteinuria and renal function, properdin excretion was strongly associated with increased urinary SC5b-9 levels (odds ratio 16.2, 95% confidence interval 3.6-74.4). Properdin excretion was associated with worse renal function. CONCLUSION: Our results suggest that urinary properdin excretion enhances intrarenal complement activation and thus may contribute to the progression of renal damage in proteinuric states.
Authors: Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Gerjan J Navis; Mohamed R Daha; Cees van Kooten; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born Journal: J Biol Chem Date: 2012-07-19 Impact factor: 5.157
Authors: Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Jelleke J Hakvoort; Gerjan J Navis; Harry van Goor; Mohamed R Daha; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born Journal: J Biol Chem Date: 2010-12-06 Impact factor: 5.157
Authors: F Corvillo; M Bravo García-Morato; P Nozal; S Garrido; A Tortajada; S Rodríguez de Córdoba; M López-Trascasa Journal: Clin Exp Immunol Date: 2016-01-22 Impact factor: 4.330
Authors: Marloes A H M Michels; Nicole C A J van de Kar; Ramon M van den Bos; Thea J A M van der Velden; Sanne A W van Kraaij; Sebastian A Sarlea; Valentina Gracchi; Michiel J S Oosterveld; Elena B Volokhina; Lambertus P W J van den Heuvel Journal: Front Immunol Date: 2019-06-17 Impact factor: 7.561
Authors: Rosa G M Lammerts; Michele F Eisenga; Mohammed Alyami; Mohamed R Daha; Marc A Seelen; Robert A Pol; Jacob van den Born; Jan-Stephan Sanders; Stephan J L Bakker; Stefan P Berger Journal: Front Immunol Date: 2019-10-24 Impact factor: 7.561
Authors: Rosa G M Lammerts; Ditmer T Talsma; Wendy A Dam; Mohamed R Daha; Marc A J Seelen; Stefan P Berger; Jacob van den Born Journal: Front Immunol Date: 2020-08-07 Impact factor: 7.561
Authors: Marloes A H M Michels; Elena B Volokhina; Nicole C A J van de Kar; Lambertus P W J van den Heuvel Journal: Pediatr Nephrol Date: 2018-08-23 Impact factor: 3.714